Minicell-Based Targeted Delivery of shRNA to Cancer Cells: An Experimental Protocol

  • Mehul Jivrajani
  • Manish Nivsarkar
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)


Bacterial minicell has emerged as a novel targeted delivery system for RNAi-based therapeutics. In this chapter, we have described the detailed protocol for the preparation of minicell-based targeted delivery system for shRNA. Initially, minicell-producing parent bacterial cells were transformed with plasmid vector containing shRNA. Subsequently, shRNA-packaged minicells were purified from parent bacterial cells. Purified minicells were characterized by fluorescence microscopy and transmission electron microscopy. In the next step, targeting ligand was conjugated on the minicell surface for the active targeting of cancer cell surface receptors. Eventually, target-specific delivery of minicells was explored in vitro in selected cancer cell line and in vivo in mice bearing tumor xenograft.


Bacterial minicells shRNA delivery Folate receptor targeted delivery RNA interference Cancer 



The authors are thankful to B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Ahmedabad, for providing all the facility for the successful completion of the work. Authors are also grateful to Dr. Lawrence Rothfield (University of Connecticut, USA) for providing E. coli PB114 as a generous gift. Additionally, authors would like to thank CSIR, India, for providing financial assistance to Mehul Jivrajani as Senior Research Fellow (# 113353/2K12/1) to carry out this work. Authors are also thankful to NIRMA University, Ahmedabad, Gujarat, India.


  1. 1.
    Elbashir SM, Harborth J, Lendeckel W, WK YA, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jivrajani M, Nivsarkar M (2016) Ligand-targeted bacterial minicells: futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells. Nanomedicine: NBM 12:2485–2498CrossRefGoogle Scholar
  3. 3.
    Oh YK, Park TG (2009) siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61:850–862CrossRefPubMedGoogle Scholar
  4. 4.
    Guo B, Zhang Y, Luo G, Li L, Zhang J (2009) Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec 292:633–639CrossRefGoogle Scholar
  5. 5.
    Zhao N, Bagaria HG, Wong MS, Zu Y (2011) A nanocomplex that is both tumor cell selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol 9(2):1–12Google Scholar
  6. 6.
    Fenske DB, Cullis PR (2008) Liposomal nanomedicines. Expert Opin Drug Deliv 5(1):25–44CrossRefPubMedGoogle Scholar
  7. 7.
    Jean M, Smaoui F, Lavertu M, Méthot S, Bouhdoud L, Buschmann MD et al (2009) Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies. Gene Ther 16(9):1097–1110CrossRefPubMedGoogle Scholar
  8. 8.
    MacDiarmid JA, Mugridge NB, Weiss JM, Sedliarou I, Wetzel S, Kochar K et al (2009) Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 27(7):643–651CrossRefPubMedGoogle Scholar
  9. 9.
    Adler HI, Fisher WD, Cohen A, Alice AH (1967) Miniature Escherichia coli cells deficient in DNA. Proc Natl Acad Sci U S A 57:321–326CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Frazer AC, Curtiss R III (1975) Production, properties and utility of bacterial minicells. Curr Top Immunol Microbiol 69:1–84CrossRefGoogle Scholar
  11. 11.
    De Boer PA, Crossley RE, Rothfield LI (1989) A division inhibitor and a topological specificity factor coded for by the minicell locus determine proper placement of the division septum in E. coli. Cell 56:641–649CrossRefPubMedGoogle Scholar
  12. 12.
    MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Bum AL, Paulin PR et al (2007) Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11:431–445CrossRefPubMedGoogle Scholar
  13. 13.
    Karagiannis ED, Anderson DG (2009) Minicells overcome tumor drug resistance. Nat Biotechnol 27(7):620–621CrossRefPubMedGoogle Scholar
  14. 14.
    Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284–293CrossRefPubMedGoogle Scholar
  15. 15.
    Jivrajani M, Shaikh MV, Shrivastava N, Nivsarkar M (2014) An improved and versatile immunosuppression protocol for the development of tumor xenograft in mice. Anticancer Res 34:7177–7184PubMedGoogle Scholar
  16. 16.
    Jivrajani MN (2014) Targeted delivery of shRNA to cancer cell. Dissertation, Nirma University AhmedabadGoogle Scholar
  17. 17.
    Jivrajani M, Shrivastava N, Nivsarkar M (2013) A combination approach for rapid and high yielding purification of bacterial minicells. J Microbiol Methods 92:340–343CrossRefPubMedGoogle Scholar
  18. 18.
    Giacalone MJ, Zapata JC, Berkley NL, Sabbadini RA, Chu YL, Salvato MS, McGuire KL (2007) Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine 25:2279–2287CrossRefPubMedGoogle Scholar
  19. 19.
    Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas—an experimental study in rats. J Cancer Res Clin Oncol 105:20–23CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mehul Jivrajani
    • 1
    • 2
  • Manish Nivsarkar
    • 1
  1. 1.Department of Pharmacology and ToxicologyB. V. Patel Pharmaceutical Education and Research Development (PERD) CentreAhmedabadIndia
  2. 2.Faculty of ScienceNIRMA UniversityAhmedabadIndia

Personalised recommendations